Senescence
Conditions
Interventions
experimental group:The compound preparation of Cistanche (5 g/sachet) should be dissolved in warm water and taken orally, twice daily (one sachet per dose), for 12 consecutive weeks.
placebo-controlled:The placebo (5 g/sachet) should be dissolved in warm water and taken orally, twice daily (one sachet per dose), for 12 consecutive weeks.
Sponsors
Wuxi People's Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: [1] Adults aged 50–70 years, male or female; [2] Signed informed consent.
Exclusion criteria
Exclusion criteria: [1] Individuals with any immunodeficiency disease or condition; [2] Pregnant or lactating women, or those planning to become pregnant during the trial period; [3] Individuals with severe cardiac, hepatic, or renal insufficiency, malignant tumors, mental disorders, or cognitive impairment; [4] Currently taking medications or supplements that may affect anti-aging, inflammation, metabolism, or mitochondrial function, including but not limited to: NAD+ precursor supplements (e.g., nicotinamide mononucleotide/NMN, nicotinamide riboside/NR, niacin/NA, etc.); antioxidant or anti-inflammatory supplements (e.g., high-dose vitamin C, vitamin E, coenzyme Q10, resveratrol, curcumin, etc.); hormonal drugs (e.g., growth hormone, sex hormone replacement therapy); immunomodulators or long-term anti-inflammatory drugs (e.g., systemic glucocorticoids, long-term use of non-steroidal anti-inflammatory drugs/NSAIDs); drugs known to affect mitochondrial function or energy metabolism (e.g., metformin, statins, etc.); other drugs or health products deemed by the investigator to potentially interfere with the study results; [5] Known or suspected allergy to the investigational product or its excipients; [6] Participation in another drug clinical trial within 1 month prior to screening enrollment; [7] Poor compliance as judged by the investigator, or any other condition that the investigator considers makes the subject unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nicotinamide adenine dinucleotide (oxidized form);Nicotinamide adenine dinucleotide (reduced form); | — |
Secondary
| Measure | Time frame |
|---|---|
| Sirtuin 1 ;Interleukin-6;High-sensitivity C-reactive protein ;Superoxide dismutase ;Malondialdehyde;Glutathione peroxidase ;Complete blood count ;Creatinine;Uric acid;Alanine aminotransferase;Aspartate aminotransferase;Blood pressure;heart rate;6-minute walk test ;Handgrip strength test;Body composition analysis;Dietary assessment; | — |
Countries
China
Contacts
Public ContactWu Chunhua
Wuxi People's Hospital
Outcome results
None listed